Imperial, United States
Imperial, United States

Time filter

Source Type

News Article | February 16, 2017
Site: www.eurekalert.org

Experimental evidence confirms what surveys have long suggested: Physicians are more likely to prescribe antibiotics when they believe there is a high expectation of it from their patients, even if they think the probability of bacterial infection is low and antibiotics would not be effective, according to a study published by the American Psychological Association. Numerous studies have shown that inappropriate and excessive antibiotic use remains one of the main causes of antibiotic resistance and is widely considered a major threat to global health. "Much effort has been spent encouraging physicians to adhere to clinical guidelines when prescribing antibiotics. However, with few notable exceptions, these efforts rarely address the non-clinical factors, such as how to tackle patients' expectations," said the study's lead author, Miroslav Sirota, PhD, of the University of Essex. The study is published in the journal Health Psychology. Researchers conducted two separate experiments involving 436 physicians in the United Kingdom. In the first experiment, practicing family physicians (50 percent male) from around the U.K. filled out a questionnaire that presented them with one of several different vignettes. All the vignettes involved a 15-year-old girl accompanied by her mother who is on her third day of symptoms of a typical ear infection with fever, ear pain and reduced hearing, however is systematically well with no ear perforation or discharge. In one version, the mother insists that the doctor help the girl to recover quickly since she has to participate in an important swim meet in four days (high expectations condition). In another vignette, there is no upcoming swim meet; rather, the girl has already finished her swimming season (low expectations condition). The physicians assessed the probability of a bacterial infection and expressed their willingness to prescribe antibiotics on a scale of zero to 10. While ear infections can be either bacterial (which may respond to antibiotics) or viral (which don't respond to antibiotics), U.K. guidelines, which is in line with the U.S. and Canadian guidelines, suggest physicians can safely withhold or delay antibiotics unless the child is systematically unwell, has perforation and/or discharge in the ear canal, or if the symptoms have persisted for four days or more, the authors noted. The order of the questions given to the physicians was manipulated randomly for each participant, so some received the bacterial probability question first and then the question on antibiotics prescribing while others saw the questions reversed. Overall, despite the order of the questions, physicians who read the vignette where the mother had higher expectations for antibiotics prescribed them even though they were no more likely than physicians in the low expectations group to think the infection was bacterial. "This was a somewhat reassuring finding as we thought that the effect of non-clinical factors might have been even more serious than we had imagined," said Sirota. "Imagine, for example, that a physician rationalized her decision to prescribe the antibiotics by increasing the perceived probability of a bacterial infection. We did not find any evidence of that happening, which is good news, and has taught us something new about the 'localized' effect of expectations." The second experiment presented a story of an adult patient with ear infection symptoms who either had low or high expectations for antibiotics - similar to the vignette in the first experiment. In this case, 52 percent of physicians prescribed antibiotics and were more likely to prescribe them if the patient expected antibiotics during the consultation. As in the previous experiment, there was no difference between the doctor's reports of bacterial probability and antibiotics prescribing. In the third vignette, involving an adult patient with typical cold symptoms who had high expectations for antibiotics, only 12 percent said they would prescribe them. "We do not intend our study to criticize physicians and how they prescribe antibiotics," stressed Sirota. "Rather, we want to point out that the over prescribing of antibiotics is a serious systemic issue: we should all work together- from patients having more realistic expectations about antibiotic effectiveness to physicians managing patients' expectations when contradicting clinical guidelines - to tackle its multiple facets." Article: "Expectations for Antibiotics Increase Their Prescribing: Causal Evidence About Localized Impact," by Miroslav Sirota, PhD, University of Essex; Thomas Round, BS, King's College London; Shyamalee Samaranayaka, MD, University of Sri Jayewardenepura; and Olga Kostopoulou, PhD, Imperial College. Health Psychology, published online Feb. 16, 2017. Full text of the article is available from the APA Public Affairs Office and at Contact: Miroslav Sirota can be contacted by email at msirota@essex.ac.uk or by phone at +44 (0) 1206 874 229. The American Psychological Association, in Washington, D.C., is the largest scientific and professional organization representing psychology in the United States. APA's membership includes nearly 115,700 researchers, educators, clinicians, consultants and students. Through its divisions in 54 subfields of psychology and affiliations with 60 state, territorial and Canadian provincial associations, APA works to advance the creation, comunication and application of psychological knowledge to benefit society and improve people's lives.


Boehringer Ingelheim Explore Overcoming Challenges to Industry in the Device Development Process at Asthma & COPD 2017 SMi will return to London once more for the 13th annual Asthma & COPD show taking place on the 29th & 30th March 2017. London, United Kingdom, February 15, 2017 --( Stefan Leiner, Chemical-Pharmaceutical Expert from Boehringer Ingelheim will be speaking at this year’s event on ‘Overcoming challenges to industry in the device development process’. Stefan will discuss: moving away from generic development, taking age group into consideration when developing a device; considerations for paediatric and elderly patients, incorporating clinical trials as a key step in obtaining device approval as well as USP regulatory updates on spacers in new devices. In the lead up to the event, SMi conducted a quick Q & A with Stefan to discuss the current landscape of the fields of asthma & COPD. SMi: “What do you see as the greatest hurdle to asthma and COPD treatments? Stefan: “One hurdle is the complexity of inhalers: Inhalation therapy requires attentive patients. The second hurdle is the long-term treatment which triggers adherence problems. And thirdly, current therapies are not curing, todays therapies target symptoms, not the cause of the diseases.” SMi: “What should be done to address this? Stefan: “We made some progress to make inhalers easier. However, a lot of research is needed to move to curing – we need new approaches.” Inhalers will be just one of the topics discussed throughout the two days. Other talking points include: regulatory updates, formulation development, therapeutic developments, personalised treatments, biologics, biomarkers, COPD updates, The Salford Lung Study and so much more from respiratory experts from MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more... A CPD certified pre-conference workshop will be hosted alongside the conference by Cambridge Consultants on ‘The future of Asthma & COPD management; from connected inhalers to therapy management’. For further information on the two day agenda or those wishing to attend, visit the event website on www.asthma-copd.co.uk/prcom Asthma & COPD 2017 is sponsored by Vitalograph and Nemera. For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk For group delegate bookings: Contact Ameenah Begum on +44 (0)20 7827 6166 or email abegum@smi-online.co.uk For media enquiries, contact Zoe Gale on +44 20 7827 6138 or zgale@smi-online.co.uk 13th annual Asthma & COPD 29-30 March 2017 London, UK www.asthma-copd.co.uk/prcom Sponsored by Vitalograph and Nemera Contact e-mail: zgale@smi-online.co.uk Contact tel: +44 (0) 207 827 6166 #asthmacopdsmi About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, February 15, 2017 --( PR.com )-- The 2017 agenda will bring together senior scientists and respiratory and inhalation specialists to discuss ongoing challenges and explore leading strategies to novel treatments and solutions for these respiratory diseases.Stefan Leiner, Chemical-Pharmaceutical Expert from Boehringer Ingelheim will be speaking at this year’s event on ‘Overcoming challenges to industry in the device development process’. Stefan will discuss: moving away from generic development, taking age group into consideration when developing a device; considerations for paediatric and elderly patients, incorporating clinical trials as a key step in obtaining device approval as well as USP regulatory updates on spacers in new devices.In the lead up to the event, SMi conducted a quick Q & A with Stefan to discuss the current landscape of the fields of asthma & COPD.SMi: “What do you see as the greatest hurdle to asthma and COPD treatments?Stefan: “One hurdle is the complexity of inhalers: Inhalation therapy requires attentive patients. The second hurdle is the long-term treatment which triggers adherence problems. And thirdly, current therapies are not curing, todays therapies target symptoms, not the cause of the diseases.”SMi: “What should be done to address this?Stefan: “We made some progress to make inhalers easier. However, a lot of research is needed to move to curing – we need new approaches.”Inhalers will be just one of the topics discussed throughout the two days. Other talking points include: regulatory updates, formulation development, therapeutic developments, personalised treatments, biologics, biomarkers, COPD updates, The Salford Lung Study and so much more from respiratory experts from MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more...A CPD certified pre-conference workshop will be hosted alongside the conference by Cambridge Consultants on ‘The future of Asthma & COPD management; from connected inhalers to therapy management’.For further information on the two day agenda or those wishing to attend, visit the event website on www.asthma-copd.co.uk/prcomAsthma & COPD 2017 is sponsored by Vitalograph and Nemera.For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.ukFor group delegate bookings: Contact Ameenah Begum on +44 (0)20 7827 6166 or email abegum@smi-online.co.ukFor media enquiries, contact Zoe Gale on +44 20 7827 6138 or zgale@smi-online.co.uk13th annual Asthma & COPD29-30 March 2017London, UKwww.asthma-copd.co.uk/prcomSponsored by Vitalograph and NemeraContact e-mail: zgale@smi-online.co.ukContact tel: +44 (0) 207 827 6166#asthmacopdsmiAbout SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group


Harwell Campus SWINDON, 27-Feb-2017 — /EuropaWire/ — A major new £100 million investment by the government into the development of an innovative multi-disciplinary science and technology research centre was announced today (Thursday 23 February 2017) by Business Secretary Greg Clark. The new Rosalind Franklin Institute (RFI) – named in honour of the pioneering British scientist whose use of X-rays to study biological structures played a crucial role in the discovery of DNA‘s ‘double helix’ structure by Francis Crick and James Watson – will bring together UK strengths in the physical sciences, engineering and life sciences to create a national centre of excellence in technology development and innovation. The new Rosalind Franklin Institute will have a hub based at the Harwell campus It will bring together UK expertise to develop new technologies that will transform our understanding of disease and speed up the development of new treatments Part of the government’s Industrial Strategy to maintain the UK’s global leadership in science, innovation and research Business Secretary Greg Clark said: The UK has always been a pioneer in the world of science, technology and medical research. It’s this excellence we want to continue to build on and why we made science and research a central part of our Industrial Strategy – strengthening links between research and industry, ensuring more home-grown innovation continues to benefit millions around the world. Named after one of the UK’s leading chemists, the new Rosalind Franklin Institute will inspire and house scientists who could be responsible for the next great discovery that will maintain the UK’s position at the forefront of global science for years to come. Delivered and managed by the Engineering and Physical Sciences Research Council (EPSRC), the RFI will bring together academic and industry researchers from across the UK to develop disruptive new technologies designed to tackle major challenges in health and life sciences, accelerate the discovery of new treatments for chronic diseases affecting millions of people around the world (such as dementia), and deliver new jobs and long-term growth to the local and UK economies. Chair of the Research Councils and EPSRC Chief Executive, Professor Philip Nelson said: The UK is currently in a world leading position when it comes to developing new medical treatments and technologies in the life sciences. However, other countries are alive to the potential and are already investing heavily. The Rosalind Franklin Institute will help secure the country as one of the best places in the world to research, discover, and innovate. The central hub at Harwell will link to partner sites at the universities of Cambridge, Edinburgh, Manchester and Oxford, Imperial College, King’s College London, and University College London. Industry partners will be on board from the outset, and the Institute will grow over time, as more universities and researchers participate. The work at new Institute will contribute directly to the delivery of EPSRC‘s ‘Healthy Nation’ prosperity outcome, its Healthcare Technologies programme, and to the Technology Touching Life initiative that spans three research councils (the Biotechnology and Biological Sciences Research Council (BBSRC), the Medical Research Council (MRC) and EPSRC) and seeks to foster interdisciplinary technology development research across the engineering, physical and life sciences. The development of the RFI has been led by Professor Ian Walmsley, FRS, from the University of Oxford, who said: This is a new joint venture between some of the UK’s leading universities and key partners in industry and research councils. The aim is to speed the application of cutting-edge physical science insights, methods and techniques to health and life sciences by providing an interface between research programmes at the forefront of these areas, co-located at Harwell and connected, dynamically, to the wider UK research base. We anticipate innovative new businesses will grow from this effort over time, as the Institute will engage with a range of key industries from inception. A collaborative joint venture model allows the RFI to make the most of interactions and draw on a wide range of existing research excellence from across the UK. Patrick Vallance, President of R&D at GSK said: We welcome the creation of the RFI which will bring world-leading, multi-disciplinary teams from industry and academia closer together, and will further strengthen the UK as a place to translate excellent science into patient benefit. Through collaboration we will be able to make advances in life science technologies much quicker than we could manage alone. Research at the RFI will initially be centred on five selected technology themes, focusing on next-generation imaging technologies – X-ray science, correlated imaging (combining X-ray, electron and light microscopy), imaging by sound and light, and biological mass spectrometry – and on new chemical methods and strategies for drug discovery. Dame Carol Robinson, FRS, who is leading the RFI‘s biological mass spectrometry theme, and received the 2004 Royal Society Rosalind Franklin Award that recognises outstanding scientific contributions and supports the promotion of women in science, technology, engineering and mathematics, said: It is fitting that this new Institute bears Rosalind Franklin’s name. She achieved so much in a relatively short life and without her work many of the advances that have taken place since would not have come about. Work in the Institute will include development of the next-generation of physical tools including mass spectrometry, instruments for X-ray science and for advanced microscopy – fields directly descended from her research interests. Notes for Editors: The Engineering and Physical Sciences Research Council (EPSRC) As the main funding agency for engineering and physical sciences research, our vision is for the UK to be the best place in the world to Research, Discover and Innovate. By investing £800 million a year in research and postgraduate training, we are building the knowledge and skills base needed to address the scientific and technological challenges facing the nation. Our portfolio covers a vast range of fields from healthcare technologies to structural engineering, manufacturing to mathematics, advanced materials to chemistry. The research we fund has impact across all sectors. It provides a platform for future economic development in the UK and improvements for everyone’s health, lifestyle and culture. We work collectively with our partners and other Research Councils on issues of common concern via Research Councils UK. The Science and Technology Facilities Council (STFC) STFC is keeping the UK at the forefront of international science and tackling some of the most significant challenges facing society such as meeting our future energy needs, monitoring and understanding climate change, and global security. The Council has a broad science portfolio and works with the academic and industrial communities to share its expertise in materials science, space and ground-based astronomy technologies, laser science, microelectronics, wafer scale manufacturing, particle and nuclear physics, alternative energy production, radio communications and radar. STFC operates or hosts world class experimental facilities including in the UK the ISIS pulsed neutron source, the Central Laser Facility, and LOFAR, and is also the majority shareholder in Diamond Light Source Ltd. It enables UK researchers to access leading international science facilities by funding membership of international bodies including European Laboratory for Particle Physics (CERN), the Institut Laue Langevin (ILL), European Synchrotron Radiation Facility (ESRF) and the European Southern Observatory (ESO). STFC is one of seven publicly-funded research councils. It is an independent, non-departmental public body of the Department for Business, Energy and Industrial Strategy (BEIS). The Biotechnology and Biological Sciences Research Council (BBSRC) BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond. Funded by Government, BBSRC invested £473M in world-class bioscience, people and research infrastructure in 2015-16. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals. More information about BBSRC strategically funded institutes. The Medical Research Council (MRC) The Medical Research Council is at the forefront of scientific discovery to improve human health. Founded in 1913 to tackle tuberculosis, the MRC now invests taxpayers’ money in some of the best medical research in the world across every area of health. Thirty-one MRC-funded researchers have won Nobel prizes in a wide range of disciplines, and MRC scientists have been behind such diverse discoveries as vitamins, the structure of DNA and the link between smoking and cancer, as well as achievements such as pioneering the use of randomised controlled trials, the invention of MRI scanning, and the development of a group of antibodies used in the making of some of the most successful drugs ever developed. Today, MRC-funded scientists tackle some of the greatest health problems facing humanity in the 21st century, from the rising tide of chronic diseases associated with ageing to the threats posed by rapidly mutating micro-organisms. www.mrc.ac.uk Diamond Light Source Diamond Light Source is the UK’s synchrotron science facility, and is approximately the size of Wembley Stadium. It works like a giant microscope, harnessing the power of electrons to produce bright light that scientists can use to study anything from fossils to jet engines to viruses and vaccines. Diamond is used by thousands of academic and industrial researchers across a wide range of disciplines, including structural biology, health and medicine, solid-state physics, materials & magnetism, nanoscience, electronics, earth & environmental sciences, chemistry, cultural heritage, energy and engineering. Many everyday commodities that we take for granted, from food manufacturing to consumer products, from revolutionary drugs to surgical tools, from computers to mobile phones, have all been developed or improved using synchrotron light. Diamond generates extremely intense pin-point beams of synchrotron light. These are of exceptional quality, and range from X-rays to ultraviolet to infrared. Diamond’s X-rays are around 10 billion times brighter than the sun. Diamond is one of the most advanced scientific facilities in the world, and its pioneering capabilities are helping to keep the UK at the forefront of scientific research. 2017 marks a double celebration for Diamond – 15 years since the company was formed, and 10 years of research and innovation. In this time, researchers who have obtained their data at Diamond have authored over 5,000 papers. The institute is funded by the UK Government through the Science and Technology Facilities Council (STFC), and by the Wellcome Trust The Harwell Campus Harwell Campus is a public private partnership between Harwell Oxford Partners, U+I Group PLC and two Government backed agencies, the Science and Technology Facilities Council (STFC) and the UK Atomic Energy Agency (UKAEA). Harwell is one of the world’s most important science and innovation locations. It has a growing reputation as the UK’s gateway to space with over 65 space and satellite applications related organisations located on campus and is now seeing rapid growth in the Life Sciences and HealthTec sector with over 1,000 people working in this field alone at Harwell. In addition to space and life sciences, the campus hosts an array of other key sectors including, Big Data and Supercomputing, Energy and Environment and Advanced Engineering and Materials. With a legacy of many world firsts, the campus comprises 710 acres, over 200 organisations and 5,500 people. Harwell Campus is the UK’s National Science Facility and is among Europe and the world’s leading sites dedicated to the advancement of science, technology and innovation. Having spent 75 years at the forefront of British innovation and discovery, Harwell Campus continues to drive scientific advancements to the benefit of the UK economy and centred around a community hub. Science experts, academics, government organisations, private sector R&D departments and investors create an environment where innovation, collaboration and discovery thrive. Harwell’s Cluster Strategy The Cluster of about 70 Space organisations at Harwell is testament to the power of co-locating industry, academia and the public sector alongside investors and entrepreneurs. The European Space Agency, RAL Space, The UK Space Agency, Airbus, Thales Alenia Space, Lockheed Martin, and Deimos Space UK can all be found on the Campus. This creates many opportunities for collaboration, increasing capability and sharing risk. Being within a Cluster brings access to high-quality common infrastructure, facilities and expertise, alongside exposure to new markets The Harwell vision is to be home to a number of Clusters that exploit the existing strengths of the Campus. The next step is a new HealthTec Cluster that will benefit from the considerable synergies across the life and physical sciences capabilities of the Campus and the Space cluster. These clusters will enrich each other, creating a powerful multidisciplinary environment tailored to problem solving that will allow the UK to compete with the best in the world. The clustering of industries, facilities and science experts has given rise to the term Harwell Effect – and is an ideal model for future science and business innovation programmes. Science clusters drive economic growth. MIT has created businesses with a combined value of $3tn, the equivalent of California’s GDP. Harwell Campus is the only location in the UK with the potential to emulate this success. To find out more about events, open days or the new developments, visit the Harwell Campus website. SOURCE: EPSRC Contact Details In the following table, contact information relevant to the page. The first column is for visual reference only. Data is in the right column. Name: EPSRC Press Office Telephone: 01793 444404


— Discover Transylvania’s Reaches Cluster is honored to announce that the international speakers have confirmed their participation at the International Conference on Trandisciplinary Research for Sustainable Tourism Development (ICTRSTD), which will be held at the Cluj-Napoca, Romania, at the Faculty of Geography, Babes-Bolyai University, on 6-8 October 2017. The event is addressing to academics, practitioners and students interested in the tourism industry and academic research. People interested to contribute to a worldwide sustainable tourism development are invited to submit their Abstract online, at http://international-conference.net/abstract-submision/, until May 1, 2017. Participants will have the occasion to publish their paper in several international academic journals, indexed in ISI-Web of Science. Don Hawkins is Professor Emeritus of Management and Tourism Studies, George Washington University, Washington, DC, USA. Since 1971, he has contributed to the development of graduate level management education and policy-related research in tourism development and strategic planning at the George Washington School of Business. In 2003, he received the first United Nations World Tourism Organization (UNWTO) Ulysses Prize for individual accomplishments in the creation and dissemination of knowledge in tourism policy and strategic management. Currently Prof. Hawkins is Vice Chairman for the Americas for the Committee of Affiliate Members. In 2012, he was appointed as Special Adviser to the Secretary General of the United Nations World Tourism Organization to oversee the UNWTO Knowledge Network, which includes 135 universities and research centers worldwide. Michael Redclift is Emeritus Professor of International Environmental Policy in the Department of Geography, at King’s College, University of London. Between 1973 and 1997 he was at Imperial College at Wye, ultimately as Professor of Environmental Sociology. His research interests include sustainable development, global environmental change, environmental security and the modern food system. In 2006 he was the first recipient of the “Frederick Buttel Award”, from the International Sociological Association (RC 24) for his “outstanding contribution to Environmental Sociology”. “We are delighted to organize such an important event for the tourism industry in Cluj-Napoca, Romania, taking in consideration that this year is the International Year of Sustainable Tourism for Development. The decision to organize this event was taken after the global community embraced the new Agenda 2030 and the Sustainable Development Goals (SDGs) and we hope to see you at the conference. Our dedicated team is dedicated to helping you, whether that is a simple inquiry about Abstract submission or an in-depth travel information”, declared Dragos Ionut Onescu, President at Discover Transylvania’s Reaches Cluster. More information about Discover Transylvania’s Reaches Cluster Discover Transylvania’s Reaches Cluster is coordinated by ODAS GLOBAL CONSULTING LTD, which is responsible to develop communication and collaboration protocol through cluster members and partners. Since 2015, they develop activities to meet their objectives and their area of interest in the region of Transylvania, and not only. You can find more information about their activities and members by visiting their official website www.discovertransylvaniacluster.ro. To learn more about this cluster organization, you can always contact our team at +40740 209 549 or info@international-conference.net. For more information, please visit http://www.international-conference.net


CrowdReviews.com Partnered with SMi to Announce: Boehringer Ingelheim Explore Overcoming Challenges to Industry in the Device Development Process at Asthma & COPD 2017 SMi will return to London once more for the 13th annual Asthma & COPD show taking place on the 29th & 30th March 2017. Stefan Leiner, Chemical-Pharmaceutical Expert from Boehringer Ingelheim will be speaking at this year’s event on "Overcoming challenges to industry in the device development process." Stefan will discuss: moving away from generic development, taking age group into consideration when developing a device; considerations for paediatric and elderly patients, incorporating clinical trials as a key step in obtaining device approval as well as USP regulatory updates on spacers in new devices. In the lead up to the event, SMi conducted a quick Q & A with Stefan to discuss the current landscape of the fields of asthma & COPD: "SMi: What do you see as the greatest hurdle to asthma and COPD treatments? Stefan: One hurdle is the complexity of inhalers: Inhalation therapy requires attentive patients. The second hurdle is the long-term treatment which triggers adherence problems. And thirdly, current therapies are not curing, todays therapies target symptoms, not the cause of the diseases. SMi: What should be done to address this? Stefan: We made some progress to make inhalers easier. However, a lot of research is needed to move to curing – we need new approaches." Inhalers will be just one of the topics discussed throughout the two days. Other talking points include: regulatory updates, formulation development, therapeutic developments, personalised treatments, biologics, biomarkers, COPD updates, The Salford Lung Study and so much more from respiratory experts from MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more. A CPD certified pre-conference workshop will be hosted alongside the conference by Cambridge Consultants on "The future of Asthma & COPD management; from connected inhalers to therapy management." For further information on the two day agenda or those wishing to attend, visit the event website on Asthma & COPD 2017 is sponsored by Vitalograph and Nemera. For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk For group delegate bookings: Contact Ameenah Begum on +44 (0)20 7827 6166 or email For media enquiries, contact Zoe Gale on +44 20 7827 6138 or 13th annual Asthma & COPD 29-30 March 2017 London, UK www.asthma-copd.co.uk/crowdreview Sponsored by Vitalograph and Nemera Contact e-mail: zgale@smi-online.co.uk Contact tel: +44 (0) 207 827 6166 #asthmacopdsmi About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Naples, FL, February 14, 2017 --( PR.com )-- The 2017 agenda will bring together senior scientists and respiratory and inhalation specialists to discuss ongoing challenges and explore leading strategies to novel treatments and solutions for these respiratory diseases.Stefan Leiner, Chemical-Pharmaceutical Expert from Boehringer Ingelheim will be speaking at this year’s event on "Overcoming challenges to industry in the device development process." Stefan will discuss: moving away from generic development, taking age group into consideration when developing a device; considerations for paediatric and elderly patients, incorporating clinical trials as a key step in obtaining device approval as well as USP regulatory updates on spacers in new devices.In the lead up to the event, SMi conducted a quick Q & A with Stefan to discuss the current landscape of the fields of asthma & COPD:"SMi: What do you see as the greatest hurdle to asthma and COPD treatments?Stefan: One hurdle is the complexity of inhalers: Inhalation therapy requires attentive patients. The second hurdle is the long-term treatment which triggers adherence problems. And thirdly, current therapies are not curing, todays therapies target symptoms, not the cause of the diseases.SMi: What should be done to address this?Stefan: We made some progress to make inhalers easier. However, a lot of research is needed to move to curing – we need new approaches."Inhalers will be just one of the topics discussed throughout the two days. Other talking points include: regulatory updates, formulation development, therapeutic developments, personalised treatments, biologics, biomarkers, COPD updates, The Salford Lung Study and so much more from respiratory experts from MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more.A CPD certified pre-conference workshop will be hosted alongside the conference by Cambridge Consultants on "The future of Asthma & COPD management; from connected inhalers to therapy management."For further information on the two day agenda or those wishing to attend, visit the event website on www.asthma-copd.co.uk/crowdreview Asthma & COPD 2017 is sponsored by Vitalograph and Nemera.For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.ukFor group delegate bookings: Contact Ameenah Begum on +44 (0)20 7827 6166 or email abegum@smi-online.co.uk For media enquiries, contact Zoe Gale on +44 20 7827 6138 or zgale@smi-online.co.uk 13th annual Asthma & COPD29-30 March 2017London, UKSponsored by Vitalograph and NemeraContact e-mail: zgale@smi-online.co.ukContact tel: +44 (0) 207 827 6166#asthmacopdsmiAbout SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk


News Article | February 23, 2017
Site: www.prnewswire.co.uk

The Victor Dahdaleh Foundation - the charitable organisation of Canadian entrepreneur and philanthropist Victor Dahdaleh - has signed a formal agreement to donate £5 million to the British Lung Foundation to fund mesothelioma research in the UK. The donation, which matches government funding announced last year, was made official at a signing ceremony in the House of Lords today. It is the largest ever made to the BLF. The funding will support the development of new treatments for the disease by a combined research team from the University of Leicester, Papworth Hospital NHS Foundation Trust in Cambridge, and the government-funded National Mesothelioma Research Centre at Imperial College in London. Today's ceremony was attended by a number of eminent peers and academics, including the sociologist Lord Giddens; entrepreneur Lord Borwick; and Professor Stephen Spiro, formerly head of respiratory medicine at UCLH. Speaking at the ceremony, Victor Dahdaleh said the Foundation was confident that the team would be able to deliver tangible benefits for patients. "We are delighted to be working in coordination with the British Lung Foundation, the UK Department of Health, and the research team to support the quest for new treatments for this terrible disease. "The UK already has leading expertise in mesothelioma research, and we believe that by working together in this way we can do even more. The professionalism we have already seen from everyone involved has been second-to-none." In an additional move towards greater collaboration between research centres, the British Lung Foundation has formed a Mesothelioma Research Network, involving the programmes at Leicester, Papworth and Imperial together with other specialist mesothelioma centres across the UK. Mesothelioma, a type of cancer commonly affecting the chest or abdomen, is on the rise in the UK, with 2,500 people dying from it each year. The disease is most closely associated with asbestos exposure and often kills with alarming speed. Dr Penny Woods, chief executive of the British Lung Foundation, said: "It is hugely exciting for all of us here to be officially marking the start of a new chapter in research into mesothelioma. Along with the government funding announced last year, this generous support from the Victor Dahdaleh Foundation will enable us to coordinate a network of highly skilled researchers and greatly increase the size and scope of clinical trials. "We are also confident that this donation will prompt further funding and allow us to continue to expand the programme. We will not rest until we find a cure." The Victor Dahdaleh Foundation has a long history of supporting health-related causes around the world. In 2015, the organisation funded the Dahdaleh Institute for Global Health - a state-of-the-art research facility at York University in Toronto, Canada. Also in Canada, the Foundation last year financed neuroscientific research at McGill University in Montreal into diseases including multiple sclerosis and Alzheimer's. In the UK, the Foundation is a long-standing supporter of research into cardiovascular disease, and has backed a range of studies carried out by teams at Imperial College and Royal Brompton Hospital. As well as healthcare, the Victor Dahdaleh Foundation promotes access to education by funding scholarships programmes that give young people from disadvantaged backgrounds the opportunity to study at top universities around the world. Victor Dahdaleh is the owner and chairman of Dadco, a privately owned investment, manufacturing and trading group established in 1915. A lifelong champion of close ties between Canada and the UK, he served as president of the Canada-United Kingdom Chamber of Commerce from 2004 to 2009. For more information on the Victor Dahdaleh Foundation, visit victordahdalehfoundation.com.


News Article | February 21, 2017
Site: www.eurekalert.org

GRAND RAPIDS, Mich. (Feb. 21, 2017)--An international collaboration of life scientists, including experts at Van Andel Research Institute, has described in exquisite detail the critical first steps of DNA replication, which allows cells to divide and most advanced life, including human, to propagate. Results of the study are published in the journal Nature Structural and Molecular Biology and reveal that a ring-shaped protein called origin recognition complex (ORC) possesses a special alpha-helix, which slips into a groove on DNA and initiates a cascade of microscopic interactions that copy DNA. "This is a story of one ring that lords over another ring," says Huilin Li, Ph.D., a professor in Van Andel Research Institute's Center for Epigenetics and a senior author of the paper. "Biologists have known for many years that both ORC and helicase are ring-shaped structures essential in the initiation and execution of DNA replication, but until now we never understood exactly how the ORC ring loads the helicase ring onto DNA." The work also reveals that ORC, with the help of Cdc6 and Cdt1, loads the helicase core onto DNA via paired interactions of the so-called winged helix domains. The resulting 14-protein structure completes the loading of the first helicase ring and is now prepared to load the next ring. This process represents the inception of an immensely complex and elegant system that is constantly ongoing at tens of thousands of points on the DNA in many cells of the human body, and it all starts with ORCs. "We hope that by mapping this process, others will eventually convert this knowledge into new treatments for DNA replication-related conditions, including many cancers and rare disorders," says Li. At the outset, the six-protein ORCs assemble into a crescent, which envelops the DNA duplex. The ORCs then recruit a seventh protein, called Cdc6, to encircle DNA. Next, this ring threads the second ring, called minichromosome maintenance protein (Cdt1-bound Mcm2-7 hexamer), around DNA, which completes loading of the first Mcm2-7 hexamer. "It's like threading a pearl onto a string; but unlike a short piece of string, the DNA strand is incredibly long and so the bead cannot be threaded on at one end," says Christian Speck, a professor at Imperial College of London's Institute of Clinical Sciences, leader of the DNA Replication group at MRC London Institute of Medical Sciences and a senior author of the paper. "Instead, it must somehow be opened up, slotted around the strand, and closed again." The study was conducted on the DNA of Saccharomyces cerevisiae, better known as baker's yeast, because of its biological and genomic similarity to larger organisms, including mammals, at an average resolution of 3.9 Angströms (about 40 billionths of a meter), which is roughly the diameter of a single atom of sodium. Magnification of this scale is currently possible only with cryoelectron microscopy (cryo-EM), a revolutionary technology VARI continues to invest in through its recently established Cryo-EM Core. Imaging for this study was conducted at Howard Hughes Medical Institute's Janelia Research Campus and at Scripps Research Institute. Study authors are Zuanning Yuan, Lin Bai, Jingchuan Sun and Huilin Li, of Van Andel Research Institute; Alberto Riera, Marta Barbon and Christian Speck, all of Imperial College of London and MRC London Institute of Medical Sciences; Jingchuan Sun of University of Pennsylvania; Saikat Nandi and Bruce Stillman, both of Cold Spring Harbor Laboratory; Christos Spanos, Zhuo Angel Chen and Juri Rappsilber, all of University of Edinburgh. Rappsilber is also affiliated with Technische Universität Berlin. Sun is now affiliated with University of Pennsylvania. This work was funded by the U.S. National Institutes of Health (GM111472 and OD12272 to Huilin Li and GM45436 to Bruce Stillman), the Biotechnology and Biological Sciences Research Council UK (P56061 to Christian Speck), and the Wellcome Trust (Investigator Award P56628 to Speck, Senior Research Fellowship 103139 to Juri Rappsilber, a Centre core grant 092076 to Rappsilber, and an instrument grant 108504 to Rappsilber). Van Andel Institute (VAI) is an independent nonprofit biomedical research and science education organization committed to improving the health and enhancing the lives of current and future generations. Established by Jay and Betty Van Andel in 1996 in Grand Rapids, Michigan, VAI has grown into a premier research and educational institution that supports the work of more than 360 scientists, educators and staff. Van Andel Research Institute (VARI), VAI's research division, is dedicated to determining the epigenetic, genetic, molecular and cellular origins of cancer, Parkinson's and other diseases and translating those findings into effective therapies. The Institute's scientists work in onsite laboratories and participate in collaborative partnerships that span the globe. Learn more about Van Andel Institute or donate by visiting http://www. .


News Article | February 23, 2017
Site: marketersmedia.com

Dr. Moreno is Co-founder and Managing Partner of Toronto-based Tahuti Global, a successful Global Advisory and Consulting firm supplying services to government institutions, investment firms and companies in the mineral resource sector. She has been involved in industry metals, with a major focus on technology and energy metal companies, for many years and has published reports on rare earths and other critical metals. She has also been a guest speaker on television and at international conferences and has been quoted in newspapers and industry blogs. Dr. Moreno held positions as a Senior Analyst, at Toronto based-investment banks and as an Investment Research Analyst at a global investment research firm. She holds a bachelor's degree and a master's degree in physics engineering, as well as a Ph.D. in materials and mechanics from Imperial College, London. "We are very pleased to have Dr. Moreno agree to join the board. Dr. Moreno's technical and economic research abilities, along with her unparalleled expertise in strategic minerals and related processes within the critical metals industry, will make her a valuable addition to the Manganese X Energy team," said Martin Kepman, CEO of Manganese X Energy Corp. "I look forward to working with Dr. Moreno as we continue to build Manganese X Energy within the manganese/EMD evolution in North America. With the addition of Dr. Moreno to our board of directors along with Peter Godbehere (advisory board member), our VP of Exploration, Roger Dahn and director Mark Billings, we are now very confident that we have formed a very well-seasoned experienced technical team, which will enable us to strive to become the first North American manganese producer to supply the North American EMD market. Our technical team will focus on metallurgical processing to produce a high grade concentrate, economical, cost saving, environmentally friendly processes which we anticipate to be very price competitive." Mr. Anthony Viele has resigned to allow Dr. Moreno to join the board as an Alternate Director and has been appointed to the Technical & Marketing Advisory Board. The Company is pleased to announce that the Company has granted 400,000 incentive stock options to various Directors and members of Technical & Marketing Advisory Board. The options are exercisable at $0.21 per option for a period of 3 years from the date of grant and have no vesting conditions. The options are being issued under the terms of the Company's Stock Option Plans which were approved by shareholders at the Company's Annual General and Special Meeting on April 21, 2016. The Option Plan has been submitted, in the normal course to the TSX Venture Exchange for approval and no options can be exercised prior to the receipt of this approval. Manganese X Energy's mission is to acquire and advance high potential manganese prospects located in North America with the intent of supplying value added materials to the lithium ion battery and other alternative energy industries as well as the steel industry. In addition our company is striving to achieve new methodologies emanating from environmentally friendly green/zero emissions, while processing manganese at a lower competitive cost. For more information, visit the website at www.manganesexenergycorp.com. ON BEHALF OF THE BOARD OF DIRECTORS Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | February 27, 2017
Site: www.prweb.com

BluPears announced it is developing a new application to teach young children communication skills leveraging artificial intelligence that emulates one-on-one interaction. The app will allow children to develop a unique story that is then converted to a game. Ongoing engagement through cognitive gamification allows the platform to continuously adapt to the learner’s abilities. Well-known research conducted by the Carnegie Institute of Technology shows that 85% of financial success can be attributed to a person’s personality, communication skills and ability to negotiate and lead. Numerous other studies have shown that a person’s emotional intelligence (EQ) – defined as awareness, control of and ability to express emotions as well judicious, empathetic management of interpersonal relationships – is more important in determining success than intelligence quotient (IQ). Research has also shown that prose and poetry education is key to building strong communication skills. “There are applications that teach science and mathematics,” said Dr. Raj Goyal, Chief Executive and Technology Officer at BluPears. “But this app will be the first of its kind to teach complex communication skills like listening, questioning, understanding and responding, by leveraging artificial intelligence to emulate one-on-one interaction.” Communication is the process of exchanging information with others. Because communication requires comprehension and response from all parties, basic computer programming isn’t adequate for developing teaching tools in the subject area. Artificial intelligence algorithms are needed for scalable personalized teaching, key to developing communication skills. “Technology is a growing part of our everyday lives, and many children spend hours watching videos and playing games on computers and mobile devices,” said BluPears Chief Operations Officer and Interim Director of Education Mus Mustapa. “The platform we’re creating to teach communication through the process of creating prose and poetry is equally engaging and entertaining for both parents and children.” Goyal and Mustapa hope BluPears ultimately gives more children a better chance at lifelong success by building strong communication skills during their early years. “Strong communicators also tend to be good collaborators, self-educators and problem solvers,” said Goyal. “If we can help instill those capabilities in more children through this technology, imagine the positive changes we might see in our world in just a single generation.” BluPears plans to donate one subscription to its artificial intelligence application to a child in need for every subscription purchased, and it has already committed to offering subscriptions to two schools in Chandigarh and Mumbai, India. The BluPears app will be available in April 2017 on the iOS, Android and web platforms through a monthly subscription. Recently, the company launched a Kickstarter campaign to build a committed and engaged user base for its final stages of development. These initial backers will have an opportunity to preview the application and provide feedback before its official release. Depending on investment level, backers will also receive a 6-month or one-year subscription to the BluPears app once it launches publicly. Additionally, they can opt to give the subscription to a school of their choice. To learn more about BluPears visit https://blupears.com/ or http://kck.st/2lakncw. About BluPears: BluPears is an educational technology startup based in San Francisco, California that leverages artificial intelligence for teaching children communication skills through prose and poetry education. The company’s initial focus is on early childhood education with plans to ultimately expand to other age groups. About Dr. Raj Goyal: Dr. Raj Goyal is the Chief Executive and Chief Technology Officer of BluPears. He has successfully launched startups in the United Kingdom, New Zealand, India and the United States including EP Bill, Avijar, LLC, which helped evolve artificial intelligence technology algorithms that will be powering the BluPears platform. He has published over 60 articles in peer-reviewed journals and holds three US patents for medical entrepreneurial work. He has a strong computer background and was the winner of the Young Investigators award for his mathematical modeling work involving arrhythmias of the heart. His background is in both medicine and engineering with degrees from Imperial College, London and the University of Michigan. He has served as an Assistant Professor at the University of Michigan’s School of Engineering and School of Medicine, and a biomedical engineering faculty member at the University of South Florida. Goyal’s focus on childhood education began with the birth of his daughter who developed strong communication skills through prose and poetry. At the age of five years old she published a poetry book called “Pink Apples.” “Blue Pears,” the inspiration for the company’s name came from this. About Mus Mustapa: Mus Mustapa is the Chief OperationzΩs Officer and Interim Director of Education at BluPears. Previously, he was a partner at IBM Global Business Services where he worked on business analytics and cognitive solutions. These processes leveraged Watson technology to be used commercially in financial services and insurance industries. He also leveraged AI technology for ThinkRewards and SlimFast to provide responsive rewards and advice based on behavior patterns and preferences. With a background in strategy management consulting, Mustapa has advised Fortune 500 C-level leaders in a number of industries including education as well as learning and development management. He holds degrees in economics and engineering from Brown University and has founded several startups focused on user interface and user experience. His interest in childhood education was inspired by his mother, who is a teacher. Growing up, he was exposed to hands-on learning and collaborative play. He has been involved in teaching as a teaching assistant and mentorship even before and through college. Since the birth of his son, Mustapa has become especially passionate about establishing better ways to engage children in education through cognitive gamification.


News Article | March 2, 2017
Site: www.businesswire.com

LONDON--(BUSINESS WIRE)--An event aimed at improving diversity in biopharma boardrooms takes place on 28th March, following a 2017 study by Liftstream forecasting that the current 1% growth in participation of women would mean gender imbalanced boards until 2056. The research, spanning 4 years, showed a net increase of just 15 women directors across 177 companies. The Liftstream event, in partnership with MedCity, brings together 200 life sciences and investment executives to discuss intentional solutions for increasing boardroom and leadership diversity within the industry. The event will explore the business case of diverse leadership, including improved innovation, strategic competitive advantage, financial performance, enhanced company culture and human capital management. Leaders implementing the UK’s prominent diversity initiatives aimed at increasing the participation of women and under-represented groups in UK business will also share their experience, insights and best-practice to enact change. “We are excited to bring this event to the UK for the first time and are tremendously pleased to partner with MedCity to do so.” said Karl Simpson, CEO of Liftstream. “Our research highlights the sector’s lack of boardroom diversity and many of the causes. We have shown there are strong business and cultural incentives for biopharma companies to increase diversity on their board of directors. People in the sector are solution-minded and collaborative, which is why we’re bringing them together to take decisive action towards increasing diversity on biotech and pharmaceutical company boards.” The Liftstream study also revealed evidence showing that diverse biotech boards outperform their counterparts in terms of shareholder returns by ~28 percent, and that they have stronger and more sustainable cultures which attract human capital. Rajesh Agrawal, Deputy Mayor for Business, said: “London is home to some truly innovative and life-changing scientific companies but it is clear that much more needs to be done to boost the number of women at board level”. He added: “Events such as this will help us to develop ways to increase the participation of women. In the meantime, the Mayor and I will keep spreading the message to all businesses that it is crucial that they remove any barriers to women by adopting the highest possible standards for fair pay, good working conditions and gender equality.” Sarah Haywood, CEO of MedCity, said: “BioPharma boardrooms do not currently reflect the real world, and although gender diversity in science and technology is a hot topic, there is still much to do within the industrial base. This isn’t an exercise in tokenism; we need to think hard about ways to encourage and support talented people into meaningful positions. I hope that by setting an example at the top of companies, the diverse pool of talent available to choose from will be expanded and there will be greater opportunity for talented people from all groups to participate in the leadership of some of our most exciting companies.” The event will feature prominent leaders from across the biotech and investment sectors with substantial expertise of diverse business cultures: Annalisa Jenkins, CEO of Dimension Therapeutics, commented: “I am thrilled to be supporting this important forum and the work of Liftstream and MedCity. My professional life has strengthened my conviction that diverse teams are winning teams. That the best male leaders open the doors for women to grow and shine. And that the next generation expect us all to create a platform for everyone to make a difference.” The event will take place at the British Medical Association, Tavistock Square, London from 3pm on March 28th. To register for the event: http://www.liftstream.com/boardstep_london.html Liftstream is an executive search recruitment practice focused exclusively on the global life sciences sector. Our clients benefit from the advanced sector knowledge we possess and the exceptional people we’re able to recruit for them into positions of leadership. Since 2003, Liftstream has been recruiting outstanding people to the unique and complex challenges of life sciences and who have contributed to innovative new treatments improving global health. Our client partnerships always focus on strengthening our clients’ teams. We achieve this through comprehensive searches and rigorous candidate assessments to identify and appoint the person most suited to our clients. Liftstream is committed to equal opportunities, diversity and inclusion. For more information about Liftstream, please visit: www.liftstream.com. MedCity exists to promote and grow life sciences investment, entrepreneurship, collaboration and industry in London, Cambridge, Oxford and the greater south east. From drug discovery to devices, diagnostics and digital health, MedCity supports life sciences and healthcare companies large and small to do business in the golden triangle. Launched in April 2014 by Imperial College Academic Health Science Centre, King’s Health Partners, UCLPartners and the Mayor of London, and in collaboration with the University of Oxford and Cambridge University; MedCity promotes life sciences in the region. For more information about MedCity, please visit: www.medcityhq.com

Loading Imperial College collaborators
Loading Imperial College collaborators